Biomind Labs Inc. (NEO:BMND)

Canada flag Canada · Delayed Price · Currency is CAD
0.1400
+0.0250 (21.74%)
At close: Jan 7, 2026
-66.27%
Market Cap12.22M
Revenue (ttm)n/a
Net Income (ttm)-158.51K
Shares Outn/a
EPS (ttm)-0.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,000
Average Volume1,819
Open0.1400
Previous Close0.1150
Day's Range0.1400 - 0.1400
52-Week Range0.1000 - 0.6500
Beta-0.74
RSI42.54
Earnings DateMar 31, 2026

About Biomind Labs

Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine based formulation that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer’s-type cognitive impairment; BMND06 is in Phase I clinical trial for treatment of... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Alejandro Antalich
Employees 5
Stock Exchange Cboe Canada
Ticker Symbol BMND
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.